Elacestrant has also demonstrated antitumor activity in breast cancer models harboring mutations in estrogen receptor alpha gene (ESR1) known to confer resistance (e.g., Y537S, D538G) and those resistant to cyclin-dependent kinase 4,6 (CDK4/6) inhibitors [7, 16, 17]. Here, ESR1 is linked to breast carcinoma.